Just recently a certain sector rotation has been observed on the equity markets. The \u201cAI trade\u201d has rather fallen out of favour, with doubts about the sustainability and, particularly, the monetarisation of artificial intelligence having put the brakes on the technology segment. Overall, the Nasdaq-100 Index has been marking time since the middle of May. Meanwhile, investors have returned to more defensive branches of the economy. The pharmaceuticals sector is among those to have benefited from this attribute. There is far more to be said for the \u201cpill pushers\u201d than just a change of favourite, though, as several industry representatives have demonstrated their innovative capacity over the last few months. One potentially ground-breaking success in the fight against cancer stands out: an mRNA vaccine from Moderna, when combined with Keytruda, the immunotherapy marketed by Merck & Co., could defeat malignant melanoma.<\/p>\n\n
The two companies involved in the clinical trial of this promising therapy are members of the Swissquote Cancer Fighters Index. In this respect the US pair have contributed to the most recent gains made by this themed investment, which on a three-month view has posted an increase of more than a quarter. The strategists at Swissquote are responsible for the concept, the composition and the regular review of the theme and place a strong emphasis on the innovative capacity of the sector. Whether immunotherapy, mRNA vaccines or the modification of T-cells (CAR-T), the fight against tumours is becoming increasingly targeted and tailored to the individual patient. Cancer continues to be among the greatest challenges facing modern medicine, \u201cbut a revolution in research, diagnosis and treatment is delivering fundamental change in how we treat this disease,\u201d the experts conclude.<\/p>\n\n
The Swissquote Cancer Fighters Index comprises companies which are improving the success of treatment for millions of patients through cutting-edge technology and pioneering therapies. Early detection is a key issue alongside the types of treatment already mentioned. The focus here is on non-invasive diagnostic methods and liquid biopsies which can be used to detect cancer at the stages when it is most treatable. So far 18 equities have made it through the systematic selection process, with US companies setting the tone. The non-American index members include Novartis and Roche. The Basel pair are actively involved in the fight against cancer. In the middle of the year there were 31 active ingredients for oncology in Novartis\u2019s research pipeline. Eleven of them are in phase III trials, with another preparation in the licensing process. Roche has been an active player on both the diagnostic and the treatment side of this field of medicine for more than 60 years. Among the group\u2019s blockbusters is the immunotherapy Tecentriq. Its successful use and the new indication mean that, even ten years after it was first licensed, this product remains a key driver of growth for Roche.<\/p>\n\n\n
The Swissquote Tracker certificate, which was issued through the Leonteq platform, allows investors to add the Swissquote Cancer Fighters Index to their portfolio. The actively managed participation product is quoted on the SIX Swiss Exchange, where it can be traded from 08.00 to 21.45 on each market day. The dividends of the companies included in the underlying are reinvested, so investors also benefit from the sometimes attractive dividends paid out in the pharmaceuticals sector. The management fee for the tracker is 0.40% p.a., and the calculation agent charges an annual fee of 0.20%. Another cost to be considered is the transaction fee, which is applied as soon as the index is adjusted and comes to up to 0.10% of the nominal volume of the particular transaction. In return, investors get a diversified selection of innovative and successful companies involved in oncology which has been expertly structured and is continuously monitored.<\/p>\n\n\n
We look forward to answering all of your questions about our products and how they are traded. Please don't hesitate to get in touch! Phone: 058 800 11 11<\/a>, email info@leonteq.com<\/a> or contact us here<\/a>.\n<\/p>\n <\/div>","url":"sq-cancer-fighter26","investmentThemeVerticalImageUrl":"https://structuredproducts-ch-live-pre.leonteq.com/product-news/sidenav-banner/Fight_Cancer_2026_Leonteq-Structured-Products_Sidenav%20Banner.jpg","thumbnailUrl":"https://structuredproducts-ch-live-pre.leonteq.com/product-news/thumbnail/Fight_Cancer_2026_Leonteq-Structured-Products_Thumbnail.jpg"}